Issues of the study of patient compliance to treatment with oral anticancer chemotherapy: Advantages of pharmacokinetics-pharmacodynamics modelisation;Les enjeux de l'observance pour les nouvelles chimiothérapies par voie orale: Intérêt du modèle pharmacocinétique- pharmacodynamique

Therapie

Volumn 62, Issue 2, 2007, Pages 77-85

  Hénin, Émilie ^a,b   You, Benoit ^a,b,c   Tranchand, Brigitte ^a,b,d   Freyer, Gilles ^a,b,c   Girard, Pascal ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

Non compliance; Oncology; Oral chemotherapy; PK PD model; Simulation

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; ERLOTINIB; IMATINIB; NAVELBINE; SORAFENIB; SUNITINIB; UFT;

CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; NEOPLASM; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; UNSPECIFIED SIDE EFFECT; ARTICLE; BIOLOGICAL MODEL; COMPUTER SIMULATION; MOUTH TUMOR; PSYCHOLOGICAL ASPECT;

ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; MOUTH NEOPLASMS; PATIENT COMPLIANCE;

EID: 34548642450     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007027     Document Type: Conference Paper

References (30)

1. Métry JM and Meyer UA, editors. Drug regimen compliance: issues in clinical trials and patient management. New York: John Wiley & Sons, 1999
2. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933-7
3. Bedell CH, Hartigan KJ, Wilkinson KL, et al. Oral chemotherapy: progress with challenges. Haematology Oncology News and Issues 2002; 1: 28-32
4. Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine. Eur J Oncol Nurs 2004; 8: S41-S53
5. Jacqmin P, Snoeck E, van Schaick EA, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD Model. J Pharmacokinet Pharmacodyn 2007; 34: 57-85
6. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5
7. Gerbrecht BM, Kangas T. Implications of capecitabine for cancer nursing practice. Eur J Oncol Nurs 2004; 8: S63-S71
8. Grober SE, Carpenter RC, Glassman M, et al. A comparison of patients' perceptions of oral cancer treatments and intravenous cancer treatments: what the health care team needs to know. Proceedings of the American Society of Clinical Oncology 2003; 22: 746 (abstract no. 3000)
9. Catania C, Didier F, Sbanotto A, et al. Fully oral chemotherapy regimens: patient's or physician's preference. Proceedings of the American Society of Clinical Oncology 2003; 22: 777 (abstract no. 3122)
10. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral anti-neoplastic agents. J Natl Cancer Inst 2002; 94: 652-61
11. Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs 2003; 7: 5-9
12. Marse H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine. Eur J Oncol Nurs 2004; 8: S16-S30
13. Cortis JD, Lacey AE. Measuring the quality and quantity of information-giving to in-patients. J Adv Nurs 1996; 24: 674-81
14. Sainio C, Eriksson E. Keeping cancer patients informed: a challenge for nursing. Eur J Oncol Nurs 2003; 7: 39-49
15. Bilodeau BA, Degner LF. Information needs, sources of information, and decisional roles in women with breast cancer. Oncol Nurs Forum 1996; 23: 691-6
16. Meredith C, Symonds P, Webster L, et al. Information needs of cancer patients in west Scotland: cross sectional survey of patients' views. BMJ 1996; 313: 724-6
17. Cassileth BR, Zupkis RV, Sutton-Smith K, et al. Information and participation preferences among cancer patients. Ann Intern Med 1980; 92: 832-6
18. Faithfull S, Deery P. Implementation of capecitabine into a cancer centre: UK experience. Eur J Oncol Nurs 2004; 8: S54-S62
19. Lim LL. Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine. Biometrics 1992; 48: 619-30
20. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310
21. Nony P, Boissel JP. Use of sensitivity functions to characterise and compare the forgiveness of drugs. Clin Pharmacokinet 2002; 41: 371-80
22. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J 1996; 17 Suppl A: 8-15
23. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345-56
24. Urquhart J, De Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med 1998; 17: 251-67
25. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 1994; 27: 202-15
26. Beal SL, Sheiner LB. The NONMEM system. American Statistician 1980; 34: 118-9
27. Beal SL, Sheiner LB. NONMEM User's Guide, Part I. University of California, San Francisco, CA 1992
28. Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996; 24: 265-82
29. Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998; 17: 2313-33
30. Pharsight Trial Simulator v2.1.2 User's Guide. Pharsight Corporation, Mountain View, CA 2001